Corcept Therapeutics Incorporated
CORT
Peringkat dalam Saham
#1745
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Harga Saham
$115.74
Kapitalisasi Pasar
$12.51B
Perubahan (1 hari)
3.25%
Perubahan (1 tahun)
47.26%
Negara
US
Perdagangan Corcept Therapeutics Incorporated (CORT)
Kategori
Healthcare
Rasio P/E untuk Corcept Therapeutics Incorporated (CORT)
Rasio P/E per October 2026 TTM: 223.52
Menurut laporan keuangan dan harga saham terbaru dari Corcept Therapeutics Incorporated, rasio P/E saat ini (TTM) adalah 223.52. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar 31.69.
Riwayat rasio P/E untuk Corcept Therapeutics Incorporated dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 223.52 | 500.37% |
| 2024 | 37.23 | 17.47% |
| 2023 | 31.69 | 48.19% |
| 2022 | 21.39 | 5.07% |
| 2021 | 20.35 | -28.54% |
| 2020 | 28.48 | 93.86% |
| 2019 | 14.69 | -34.02% |
| 2018 | 22.27 | 40.23% |
| 2017 | 15.88 | -83.90% |
| 2016 | 98.61 | -218.81% |
| 2015 | -83.00 | 759.85% |
| 2014 | -9.65 | 38.61% |
| 2013 | -6.96 | 99.20% |
| 2012 | -3.50 | -60.30% |
| 2011 | -8.81 | -13.31% |
| 2010 | -10.16 | 40.51% |
| 2009 | -7.23 | 204.34% |
| 2008 | -2.38 | -74.02% |
| 2007 | -9.15 | 709.65% |
| 2006 | -1.13 | -72.50% |
| 2005 | -4.11 | -44.64% |
| 2004 | -7.42 | -31.19% |
| 2003 | -10.78 | 142.75% |
| 2002 | -4.44 | -49.65% |
| 2001 | -8.82 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 24.47 | -89.05% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 33.58 | -84.98% |
HK
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.